Bio-Techne (TECH) Proxy filing summary

Executive summary

• Planned acquisition by Merck KGaA, Darmstadt, Germany, is progressing with regulatory approval received in Germany and other approvals pending.

• Shareholder vote on the transaction is scheduled for September 23, with anticipated closing by late 2026 or early 2027, subject to customary conditions.

• Integration planning is underway, focusing on readiness and not operational integration until after transaction close.

• Forward-looking statements highlight potential risks, including regulatory, operational, and market uncertainties.

Voting matters and shareholder proposals

• Shareholders will vote on the approval of the proposed acquisition on September 23.

• Approval by shareholders is a key condition for the transaction to proceed.

Board of directors and corporate governance

• Directors and executive officers of both companies may participate in proxy solicitation.

• Information about directors, executive officers, and their holdings is available in prior SEC filings and will be updated as needed.